Pramipexole in addition to mood stabilisers for treatment-resistant bipolar depression: the PAX-BD randomised double-blind placebo-controlled trial

Pramipexole in addition to mood stabilisers for treatment-resistant bipolar depression: the PAX-BD randomised double-blind placebo-controlled trial

Background There are limited options currently recommended in National Institute for Health and Care Excellence guidelines for the treatment of bipolar depression. Pramipexole has been shown to improve mood symptoms in two small pilot studies in such patients. Objectives Primary: to evaluate the cli...

Full description

Saved in:
Bibliographic Details
Main Authors: Hamish McAllister-Williams, Nicola Goudie, Lumbini Azim, Victoria Bartle, Michael Berger, Chrissie Butcher, Thomas Chadwick, Emily Clare, Paul Courtney, Lyndsey Dixon, Nichola Duffelen, Tony Fouweather, William Gann, John Geddes, Sumeet Gupta, Beth Hall, Timea Helter, Paul Hindmarch, Eva-Maria Holstein, Ward Lawrence, Phil Mawson, Iain McKinnon, Adam Milne, Aisling Molloy, Abigail Moore, Richard Morriss, Anisha Nakulan, Judit Simon, Daniel Smith, Bryony Stokes-Crossley, Paul Stokes, Andrew Swain, Zoë Walmsley, Christopher Weetman, Allan H Young, Stuart Watson
Format: Article
Language:English
Published: NIHR Journals Library 2025-05-01
Series:Health Technology Assessment
Subjects:
pramipexole
treatment-resistant bipolar depression
bipolar disorder
bipolar depression
depression
adults
randomised controlled trial
placebo controlled
multisite
treatment outcome
quality of life
economic evaluation
qualitative
ppi
psychiatry
health economics
Online Access:https://doi.org/10.3310/HBFC1953
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.3310/HBFC1953

Similar Items